These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 15767241

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M, O'Donnell JC, Jones P.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [Abstract] [Full Text] [Related]

  • 3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 4. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB, Frial T, Miller PS.
    Can J Clin Pharmacol; 2007 Sep; 14(2):e205-14. PubMed ID: 17556788
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
    Hirsch M, O'donnell J, Olsson A.
    Int J Cardiol; 2005 Oct 10; 104(3):251-6. PubMed ID: 16186052
    [Abstract] [Full Text] [Related]

  • 7. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS, Smith DG, Jones P.
    Am J Cardiol; 2005 Jun 01; 95(11):1314-9. PubMed ID: 15904635
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
    Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Davidson MH.
    Clin Ther; 2007 Nov 01; 29(11):2385-94. PubMed ID: 18158079
    [Abstract] [Full Text] [Related]

  • 11. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M, DISCOVERY PENTA investigators.
    Curr Med Res Opin; 2005 Aug 01; 21(8):1307-15. PubMed ID: 16083541
    [Abstract] [Full Text] [Related]

  • 12. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, Gogineni S, Wang P.
    Clin Ther; 2006 Jun 01; 28(6):933-42. PubMed ID: 16860175
    [Abstract] [Full Text] [Related]

  • 13. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE, Phillips JO, Mohiuddin SM, Ryschon KL, Pedersen CA.
    Clin Ther; 1999 Mar 01; 21(3):536-62. PubMed ID: 10321422
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul 01; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 16. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A, Jovell AJ, García-Altés A, García-Closas R, Serra-Majem L.
    Clin Ther; 1999 Nov 01; 21(11):1924-36. PubMed ID: 10890264
    [Abstract] [Full Text] [Related]

  • 17. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting.
    Harley CR, Gandhi SK, Anoka N, Bullano MF, McKenney JM.
    Am J Manag Care; 2007 Dec 01; 13 Suppl 10():S276-81. PubMed ID: 18095778
    [Abstract] [Full Text] [Related]

  • 18. [Clinical trials with rosuvastatin: efficacy and safety of its use].
    Schweiger C.
    Ital Heart J; 2003 Dec 01; 4 Suppl 7():33S-46S. PubMed ID: 14983745
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Bays HE.
    Curr Med Res Opin; 2007 Sep 01; 23(9):2125-33. PubMed ID: 17655813
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
    Stein EA, Amerena J, Ballantyne CM, Brice E, Farnier M, Guthrie RM, Harats D, Ma PT, Le Maulf F, Melezínková H, Gold A, Sager P.
    Am J Cardiol; 2007 Nov 01; 100(9):1387-96. PubMed ID: 17950795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.